Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Likely To Cede U.S. Rights to Vernakalant, Cardiome CEO Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Analysts speculate that Merck will buy out Astellas' U.S. vernakalant rights in a move that would be positive for Cardiome.

You may also be interested in...



Merck Consolidates All Rights To Vernakalant By Assuming North American Rights From Astellas

Already holding worldwide rights to the oral formulation and rest-of-world rights to intravenous vernakalant, Merck will partner with Cardiome Pharma to obtain FDA approval of IV vernakalant.

Merck Consolidates All Rights To Vernakalant By Assuming North American Rights From Astellas

Already holding worldwide rights to the oral formulation and rest-of-world rights to intravenous vernakalant, Merck will partner with Cardiome Pharma to obtain FDA approval of IV vernakalant.

Cardiome/Astellas' Kynapid Approval Seems Likely For Limited Indication, If Additional Trial Holds Up

Atrial fibrillation drug has been languishing after "approvable" letter - but approval now seems in the cards for limited indication.

Topics

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel